COMPANY PROFILE // THE 014 REPORT

Regeneron Pharmaceuticals, Inc.

REGN (Nasdaq)

Assembled from 6 government sources in 0.2 s

Built from public records at 2026-11-21 06:33 ET. Every figure links to its source. Flags and checks built 2026-11-21 13:59 ET. Sources

FLAGS · DISCLOSURE · SUMMARY

Missing or hidden

  • InfoGLEIF: no direct parent reported; reporting exception reason NO_KNOWN_PERSON.2026-11-19 · source

✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website

No SAM registration, no IRS return, no website on record.

REGENERON PHARMACEUTICALS, INC. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NY, based in Tarrytown, NY; listed as REGN (Nasdaq).[source] It reported revenue of $14.34 billion for the fiscal year ended 2025-12-31.[source] It has filed 104 documents with the SEC in the last 12 months; the latest is a S-8, filed 2026-11-19.[source] 8 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, Dodge & Cox (as of 2026-06-30).[source] 22 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]

0federal award recipients matched by name in USAspending
8lobbying filings name it as client (possible match)
104SEC filings in the last 12 months
$27.31Bheld by its 10 largest 13F holders (as of 2026-06-30)
SEC filings by month, 24 months
2024-12: 142025-01: 122025-02: 42025-03: 12025-04: 92025-05: 12025-06: 22025-07: 02025-08: 42025-09: 02025-10: 62025-11: 62025-12: 122026-01: 172026-02: 82026-03: 22026-04: 82026-05: 22026-06: 12026-07: 52026-08: 82026-09: 62026-10: 82026-11: 252024-122026-11
Flags by level
  • red0
  • amber0
  • info1
Largest 13F holders, value as filed
  • BlackRock, Inc.$5.68B
  • VANGUARD CAPITAL MANAGEMENT LLC$4.13B
  • Dodge & Cox$3.04B
  • STATE STREET CORP$3.01B
  • Invesco Ltd.$2.46B
  • JPMORGAN CHASE & CO$2.38B
  • VANGUARD PORTFOLIO MANAGEMENT LLC$1.98B
  • FRANKLIN RESOURCES INC$1.73B

RECORD · WEB

Ask about this entity

Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).

PEOPLE · COUNSEL · LINKS

Leadership, advisers and links

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. (Wikipedia, CC BY-SA 4.0)

Officers and directors (Forms 3, 4, 5)

As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.

Links

EVERY LIST AND SOURCE · DATED

Checked and clear

26 lists and sources checked: 22 CLEAR, 4 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.

List or sourceResultCheckedWhat matched
OFAC SDN (Treasury)CLEAR2026-11-20
SAM.gov exclusionsCLEAR2026-11-21
HHS-OIG LEIECLEAR2026-11-13
FARA registrants (DOJ)CLEAR2026-11-21
Regulated facility: compliance, penalties and TRI parent (EPA)POSSIBLE MATCH2026-11-18REGENERON PHARMACEUTICALS; REGENERON PHARMACEUTICALS, INC.
Hazardous-waste handler facility (EPA RCRAInfo, sample)CLEAR2026-11-18
Consumer complaints about a company (CFPB)CLEAR2026-11-18
Corporate enforcement action (DOJ, SEC, CFTC, EPA)POSSIBLE MATCH2026-11-18Regeneron Pharmaceuticals, Inc.
SEC litigation release (respondent)CLEAR2026-11-18
Federal Reserve Board enforcement action (press release, 2022 onward)CLEAR2026-11-18
Enforcement order against a savings association (OCC, OTS archive to 2011)CLEAR2026-11-18
State environmental enforcement actions (Maryland MDE, Connecticut DEEP)CLEAR2026-11-18
Firm sanctioned or debarred by the IDB Group (incl. cross-debarments by WBG, ADB, EBRD, AfDB as listed by the IDB)CLEAR2026-11-18
UK sanctions designation (FCDO UK Sanctions List)CLEAR2026-11-18
US export screening list party (Consolidated Screening List, ITA)CLEAR2026-11-18
FDA recallCLEAR2026-11-18
FDA import alert or listed firm (Red / Yellow / Green list)CLEAR2026-11-18
Consumer product recall or recalling firm (CPSC, full history)CLEAR2026-11-18
Consumer product recall (CPSC)CLEAR2026-11-18
Vehicle recall, defect investigation or manufacturer (NHTSA ODI)CLEAR2026-11-18
Vehicle recall (NHTSA)CLEAR2026-11-18
FinCEN enforcement action (civil money penalty or consent order, 1999 onward)CLEAR2026-11-18
Union representation election (NLRB)CLEAR2026-11-18
NYC summons against an organization, adjudicated at OATH (all city agencies)CLEAR2026-11-18
Data breach notice to a state Attorney GeneralPOSSIBLE MATCH2026-11-18Regeneron Pharmaceuticals, Inc.; Regeneron Pharmaceuticals
Data breach notice (California Attorney General)POSSIBLE MATCH2026-11-18Regeneron Pharmaceuticals, Inc.

EVERY IDENTIFIER · LINKED

ID crosswalk

IdentifierValueRecord
SEC CIK0000872589source
LEI549300RCBFWIRX3HYQ56source
EIN13-3444607source
NY DOS ID1226128record
California SOS entity0471116-01-999-0471116record
Connecticut business ID1054405record
LDA clientpossible match67618record
LDA clientpossible match65271record
LDA clientpossible match64079record
Business address (SEC)777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591source

Does not exist in the records we hold: UEI, FDIC certificate.

EACH FEEDS WATCH

Dates coming up

PEERS BY SIC CODE

Industry context

SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.

#42 of 568
federal dollars
#6 of 568
lobbying filings
#70 of 568
SEC filings in 12 months
#359 of 568
flags

Peers, each with its 014

  • PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
  • Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
  • ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
  • ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
  • NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
  • Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
  • Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
  • SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
  • Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
  • UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
  • Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)

SHARED PEOPLE · SHARED ADDRESS

Network neighbours

Shared directors and officers

EVERY SOURCE · NEWEST FIRST

One timeline

  • 2026-11-19 filing S-8 · SEC EDGAR
  • 2026-11-17 filing 144 · SEC EDGAR
  • 2026-11-17 filing 144 · SEC EDGAR
  • 2026-11-16 filing 144 · SEC EDGAR
  • 2026-11-16 filing 144 · SEC EDGAR
  • 2026-11-04 filing 144 · SEC EDGAR
  • 2026-11-04 filing 144 · SEC EDGAR
  • 2026-11-03 filing 144 · SEC EDGAR
  • 2026-11-02 filing 144 · SEC EDGAR
  • 2026-11-02 filing 144 · SEC EDGAR
  • 2026-11-02 filing 144 · SEC EDGAR
  • 2026-10-30 filing 144 · SEC EDGAR
  • 2026-10-30 filing 144 · SEC EDGAR
  • 2026-10-30 filing 144 · SEC EDGAR
  • 2026-10-30 filing Quarterly report (10-Q) · SEC EDGAR
  • 2026-10-30 filing 8-K items 2.02,9.01 · SEC EDGAR
  • 2026-10-14 filing 144 · SEC EDGAR
  • 2026-10-06 filing 8-K items 1.01,2.02,8.01 · SEC EDGAR
  • 2026-09-30 officer change 8-K items 5.02,9.01 · SEC EDGAR
  • 2026-09-03 filing 144 · SEC EDGAR
  • 2026-09-02 filing 144 · SEC EDGAR
  • 2026-09-02 filing 144 · SEC EDGAR
  • 2026-08-20 filing N-PX · SEC EDGAR
  • 2026-08-10 filing 144 · SEC EDGAR
  • 2026-08-10 filing 144 · SEC EDGAR
  • 2026-07-30 filing Quarterly report (10-Q) · SEC EDGAR
  • 2026-07-30 filing 8-K items 2.02,9.01 · SEC EDGAR
  • 2026-07-06 filing 8-K items 2.02 · SEC EDGAR
  • 2026-07-02 filing 144 · SEC EDGAR
  • 2026-06-17 filing 8-K items 5.07 · SEC EDGAR
157 earlier entries

RENDERED FROM THIS PAGE

Relationship graph

BlackRock, Inc. · holderVANGUARD CAPITAL MANAGEMENT LLC · holderDodge & Cox · holderSTATE STREET CORP · holderInvesco Ltd. · holderREGENERON INDIA PRIVATE LIMITED · subsidiaryREGENERON IRELAND DESIGNATED ACTIV · subsidiaryCHECKMATE GOVERNMENT RELATIONS · lobbying firmREGENERON PHARMACEUTICALS, INC · lobbying firmARNOLD & PORTER KAYE SCHOLER LLP · lobbying firmBGR GOVERNMENT AFFAIRS · lobbying firmFenimore Christopher R. · officer or directorLAROSA JOSEPH J · officer or directorMURPHY ANDREW J · officer or directorMcCourt Marion · officer or directorPitofsky Jason · officer or directorRoyalty Pharma plc · shared boardSHERWIN WILLIAMS CO · shared boardNEUROCRINE BIOSCIENCES INC · shared boardPRUDENTIAL FINANCIAL INC · shared boardRegeneron Pharmaceuticals, Inc.

Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.

DATA MOTION // NEWEST FIRST

What changed

Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.

COUNTS FROM THIS PAGE

Relationships at a glance

10largest institutional holders (13F as filed)
2other entities in the GLEIF ownership tree (ID tier)
0awarding federal agencies
7hiring lobbying firms: possible match: matched by name only, not merged
PRICE · FILINGS · POSTS · NEWS

Market & news

Price
NASDAQ:REGN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
Open in
Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

Financials
Filed figures: published SEC values, each linked to its filing.
Official posts
Links to posts from the company's and agencies' verified accounts: not connected yet.
News
Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER

1. Identity

4confirmed members (SEC registrant + GLEIF ownership tree)
3legal entities (LEI) in the ownership tree
34dated filings and events

29 possible matches held apart, matched by name only, not counted above.

IdentifierValueHow it was resolvedSource
SEC CIK872589id:sec-anchor: the SEC registrant record of this companySEC EDGAR
Ticker / exchangeREGN / NasdaqSEC company record: ticker and exchange as listed on the SEC company recordSEC EDGAR
LEI335800DYBVNUYLGVHJ55id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 335800DYBVNUYLGVHJ55)GLEIF
LEI635400NABUOXXFAMHX81id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 635400NABUOXXFAMHX81)GLEIF
LEI (root of the ownership tree)549300RCBFWIRX3HYQ56id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300RCBFWIRX3HYQ56)GLEIF
EIN133444607carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589SEC EDGAR / IRS
CUSIP75886F107carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589SEC EDGAR
UEIN3F9MH7E6HD6carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000872589USAspending

possible match: matched by name only, not merged (14)

Identifiers carried by records that share the company's exact name. Not merged into the identity above.

IdentifierValueHow it was resolvedSource
LDA client id65271 (REGENERON PHARMACEUTICALS INC. (lobbying via CHECKMATE GOVERNMENT RELATIONS))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id200807 (REGENERON PHARMACEUTICALS, INC (lobbying via REGENERON PHARMACEUTICALS, INC))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id210738 (REGENERON PHARMACEUTICALS, INC. (lobbying via ARNOLD & PORTER KAYE SCHOLER LLP))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id67618 (REGENERON PHARMACEUTICALS, INC. (lobbying via BGR GOVERNMENT AFFAIRS))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id208641 (REGENERON PHARMACEUTICALS, INC. (lobbying via STEWART STRATEGIES AND SOLUTIONS, LLC))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id64079 (REGENERON PHARMACEUTICALS, INC. (lobbying via THE WASHINGTON TAX & PUBLIC POLICY GROUP))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id196249 (REGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
LDA client id162758 (REGENERON PHARMACEUTICALS, INC. (lobbying via an individual registrant))name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'Lobbying Disclosure Act (LDA)
EPA FRS id110070120473 (REGENERON PHARMACEUTICALS)name-exact: exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name)EPA ECHO facilities
EPA FRS id110071679215 (REGENERON PHARMACEUTICALS INC)name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'EPA ECHO facilities
EPA FRS id110014446894 (REGENERON PHARMACEUTICALS INC)name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'EPA ECHO facilities
EPA FRS id110000880887 (REGENERON PHARMACEUTICALS INC.)name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'EPA ECHO facilities
EPA FRS id110071845659 (REGENERON PHARMACEUTICALS, INC.)name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'EPA ECHO facilities
EPA FRS id110071067985 (REGENERON PHARMACEUTICALS, INC.)name-exact:legal-name: same registered legal name as 'REGENERON PHARMACEUTICALS, INC.'EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING

2. Filed figures

Key figures (annual filing)

FigureValuePeriod or as ofSourceBasisRetrievedReport
Revenue (fiscal year ended 2025-12-31)$14,342,900,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTaxas filed2026-11-21 11:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$4,504,900,0002025-12-3110-K, XBRL NetIncomeLossas filed2026-11-21 11:33 UTCReport an error
Total assets (at 2025-12-31)$40,558,700,0002025-12-3110-K, XBRL Assetsas filed2026-11-21 11:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$31,256,900,0002025-12-3110-K, XBRL StockholdersEquityas filed2026-11-21 11:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$3,118,100,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValueas filed2026-11-21 11:33 UTCReport an error

Company profile facts (SEC)

FigureValuePeriod or as ofSourceBasisRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error
State of incorporationNY2026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error
Business address777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 105912026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error
ExchangesNasdaq2026-11-19SEC EDGAR company profileas filed2026-11-21 11:33 UTCReport an error

Other filed values

FigureValuePeriod or as ofSourceBasisRetrievedReport
Operating cash flow (fiscal year ended 2025-12-31)$4,978,900,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivitiesas filed2026-11-21 11:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$898,400,0002025-12-3110-K, XBRL PaymentsToAcquireProductiveAssetsas filed2026-11-21 11:33 UTCReport an error
Long-term debt (at 2025-12-31)$1,985,900,0002025-12-3110-K, XBRL LongTermDebtNoncurrentas filed2026-11-21 11:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$266,800,0002025-12-3110-K, XBRL OperatingLeaseLiabilityas filed2026-11-21 11:33 UTCReport an error
Plan (pension, plan no. 001)REGENERON PHARMACEUTICALS, INC. 401(K) SAVINGS PLAN: 14,387 participants, assets $3,199,977,5832025-12-31DOL EBSA Form 5500 public datasets (dataset)as filed2026-11-21 11:33 UTCReport an error
Plan (welfare, plan no. 501)REGENERON PHARMACEUTICALS, INC. WELFARE BENEFIT PLAN: 11,716 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)as filed2026-11-21 11:33 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$279,399,579.882026-09-30USAspending recipient profileas filed2026-11-21 11:33 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)152026-09-30USAspending recipient profileas filed2026-11-21 11:33 UTCReport an error

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-30 · accession 0000872589-26-000034

ItemValuePeriodFormFiledAccessionRetrievedReport
Revenue$5,115,800,0003 months ended 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error
Net income (loss)$1,948,700,0003 months ended 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error
Interest expense$10,600,0003 months ended 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error
Cash and cash equivalents$3,659,100,000at 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error
Contract liabilities, current$749,800,000at 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error
Contract liabilities, noncurrent$220,200,000at 2026-09-3010-Q2026-10-300000872589-26-0000342026-11-21 11:33 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.

No estimates: every value is as filed and links to the filing it came from.

Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.

NEWEST FIRST · EACH LINKS TO ITS FILING

3. Registration and filing timeline

9 earlier entries

8-K item text, as filed (excerpts)

Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.

POSSIBLE MATCHES · NAME ONLY

6. Lobbying (LDA)

8 lobbying records carry this company's exact name, hiring 7 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.

possible match: matched by name only, not merged (8)

Possible match based on name, not a shared identifier. Compare the records.

POSSIBLE MATCHES · GROUPED BY SOURCE

8. Enforcement by agency

EPA ECHO facilities (6)

possible match: matched by name only, not merged (6)

Possible match based on name, not a shared identifier. Compare the records.

Breach states (4)

possible match: matched by name only, not merged (4)

Possible match based on name, not a shared identifier. Compare the records.

California data-breach notices (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

DOJ and agency corporate enforcement (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.

AS FILED · LARGEST HOLDERS

10. 13F institutional holders

RankHolder (13F filer)Value heldAs ofSourceRetrievedReport
1BlackRock, Inc.$5,682,635,6422026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
2VANGUARD CAPITAL MANAGEMENT LLC$4,133,919,9262026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
3Dodge & Cox$3,037,348,7652026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
4STATE STREET CORP$3,014,621,3562026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
5Invesco Ltd.$2,457,161,8722026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
6JPMORGAN CHASE & CO$2,384,577,3782026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
7VANGUARD PORTFOLIO MANAGEMENT LLC$1,979,934,6682026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
8FRANKLIN RESOURCES INC$1,728,352,7442026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
9GEODE CAPITAL MANAGEMENT, LLC$1,632,283,0602026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error
10Nuveen, LLC$1,259,533,9942026-06-30SEC 13F filing2026-11-21 11:33 UTCReport an error

13F as filed: the holder's own report of its position value at the quarter end.

GLEIF OWNERSHIP TREE · ID TIER

11. Subsidiaries

3 legal entities in the company's GLEIF ownership tree, joined by LEI (an official identifier).

Exhibit 21 subsidiaries: not held yet.

DOL H-1B (LCA) · WARN NOT HELD

12. Labor

MeasureValueAs ofSourceRetrievedReport
Employer name (as filed)Regeneron Pharmaceuticals, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Certified LCAs292026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Total worker positions on certified LCAs292026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Top job titles (title, LCA count)Process Development Engineer III (2); Senior Scientist (2); Director Data Management (2); Manager Central Monitoring Data Analysis (2); Senior Analytical Scientist (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Wage offered, annualized (n, min, median, max)median $155,000 (range $95,000-$250,000, 29 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Worksite statesFL; NJ; NY; OH; PA; VA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error

Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.

WARN layoff notices: not held yet.

POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS

13. Permits and local records

9 state and city records carry this company's exact name, from 6 sources. Possible matches only.

State licences (4)

possible match: matched by name only, not merged (4)

Possible match based on name, not a shared identifier. Compare the records.

California business registrations (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

Connecticut business registrations (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

ClinicalTrials.gov (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

  • possible matchRegeneron Pharmaceuticals · exact name match to 'REGENERON PHARMACEUTICALS, INC.' (no other entity shares the name) · sx:ctgov:h940cd02a160ba44c Compare

Eia plants (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

New York corporations (1)

possible match: matched by name only, not merged (1)

Possible match based on name, not a shared identifier. Compare the records.

WHAT THIS PAGE READ

Sources

As of 2026-11-21 (record built 2026-11-21T11:33:17Z). Sources used: SEC EDGAR, DOL OFLC LCA Disclosure Data, DOL EBSA Form 5500 public datasets, SEC 13F holdings, USAspending, GLEIF.

Not checked: FTC enforcement actions; DOJ press releases (beyond FARA and the corporate enforcement set); federal and state court records; UCC filings, liens and bankruptcy dockets; IRS automatic revocation list; state annual-report dates; company formation dates (only where a state registry record states one).

JSON · MCP · API

API and agents

The same profile as JSON: GET /company/872589.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000872589. Every source URL used is listed in the file.

Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.